Нажмите на эту строку чтобы перейти к Новостям сайта "Русский врач"

Перейти
на сайт
журнала
"Врач"
Перейти на сайт журнала "Медицинская сестра"
Перейти на сайт журнала "Фармация"
Перейти на сайт журнала "Молекулярная медицина"
Перейти на сайт журнала "Вопросы биологической, медицинской и фармацевтической химии"
Журнал включен в российские и международные библиотечные и реферативные базы данных

ВАК (Россия)
РИНЦ (Россия)
Эко-Вектор (Россия)

LONG-TERM RESULTS OF TREATING PATIENTS WITH BONE OSTEOSARCOMA TAKING INTO ACCOUNT THE CONTENT OF MATRIX METALLOPROTEINAS AND THEIR TISSUE INHIBITORS IN BLOOD SERUM

DOI: https://doi.org/10.29296/25877313-2019-02-06
Download full text PDF
Issue: 
2
Year: 
2019

I.V. Babkina Dr.Sc. (Med.), Professor, Department of Clinical Biochemistry and Laboratory Diagnostics, A.I. Evdokimov Moscow State Medical and Dental University of the Ministry of Health of Russia (Moscow) E-mail: docbabkina@rambler.ru I.S. Chernomaz Post-graduate Student, Department of Clinical Biochemistry and Laboratory Diagnostics, A.I. Evdokimov Moscow State Medical and Dental University of the Ministry of Health of Russia (Moscow) E.S. Gershtein Dr.Sc. (Biol.), Professor N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia (Moscow) I.N. Kuznetsov Ph.D. (Med.), Senior Laboratory Assistant, Department of Clinical Biochemistry and Laboratory Diagnostics, A.I. Evdokimov Moscow State Medical and Dental University of the Ministry of Health of Russia (Moscow) A.V. Bondarev Oncologist, Moscow Oncological Hospital № 62 (Moscow) Yu.M. Shchupak Oncologist, Head of Surgical Department, Moscow Oncological Hospital № 62 (Moscow) Yu.N. Soloviev Dr.Sc. (Med.), Professor, Academician of RAS, N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia (Moscow) I.V. Boulitcheva Dr.Sc. (Med.), Pathologist, N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia (Moscow) M.D. Aliev Dr.Sc. (Med.), Professor, Academician of RAS, N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia (Moscow) N.E. Kushlinskii Dr.Sc. (Med.), Professor, Correspondent Member of RAS, N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia (Moscow)

Relevance. Osteosarcoma is the most common primary bone tumor. The addition of standard treatment regimens with new drugs to achieve high results of treatment so far has not helped. Only concerted joint international efforts aimed at identifying new targets and introducing new treatments can contribute to advances in the treatment of bone tumors. The purpose of the study was to study the long-term results of treatment of patients with osteo-sarcoma, taking into account the content of MMP-2, -7, -9, as well as their serum tissue inhibitors TIMP-1, -2 in order to identify a possible relationship with the clinical and morphological characteristics of the tumor and the prognosis of the disease. Material and methods. A total of 58 patients with osteosarcoma and 76 practically healthy people of the corresponding age who made up the control group were examined. In all patients, the diagnosis was established for the first time and confirmed by the data of histological examination of the tumor. Studies of MMP-2, -7, -9, TIMP-1, -2 were performed in blood serum prior to the start of specific treatment by ELISA with reagent kits from R & D (USA). For statistical processing of the obtained results, the program «Statistica» 7.0 was used. Results. The levels of MMP-2 and MMP-9 in serum of patients with osteosarcoma were significantly lower, and MMP-7, TIMP-1 and TIMP-2 were significantly higher than in practically healthy people. In patients with osteosarcoma with I-II stages of the disease, a significant decrease in overall sur-vival rates was found with MMP-2 serum levels
Keywords: 
MMP-2
-7
-9
TIMP-1
-2
osteosarcoma
prognosis

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Tieken C., Verboom M.C., Ruf W., Gelderblom H., Bovée J.V., Reitsma P.H., Cleton-Jansen A.M., Versteeg H.H. Tissue factor associates with survival and regulates tumour progression in osteosarcoma. Thromb. Haemost. 2016;115(5):1025-1033.
  2. Tirtei E., Asaftei S.D., Manicone R., Cesari M., Paioli A., Rocca M., Ferrari S., Fagioli F. Survival after second and subsequent recurrences in osteosarcoma: a retrospective multicenter analysis. Tumori. 2018;104(3):202-206.
  3. Meazza C., Cefalo G., Massimino M., Daolio P., Pastorino U., Scanagatta P., Morosi C., Podda M., Ferrari A., Teren-ziani M., Spreafico F., Casanova M., Parafioriti A., Collini P., Gandola L., Bastoni S., Biassoni V., Schiavello E., Chiaravalli S., Puma N., Bergamaschi L., Luksch R. Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2. Med. Oncol. 2017; 34(12):191. doi: 10.1007/s12032-017-1052-9.
  4. Martin-Broto J., Redondo A., Valverde C., Vaz M.A., Mora J., Garcia Del Muro X., Gutierrez A., Tous C., Carnero A., Marcilla D., Carranza A., Sancho P., Martinez-Trufero J., Diaz-Beveridge R., Cruz J., Encinas V., Taron M., Moura D.S., Luna P., Hindi N., Lopez-Pousa A. Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). Ann. Oncol. 2017;28(12):2994-2999.
  5. Ferrari S., Bielack S.S., Smeland S., Longhi A., Egerer G., Sundby Hall K., Donati D., Kevric M., Brosjö O., Comandone A., Werner M., Monge O., Palmerini E., Berdel W.E., Bjerkehagen B., Paioli A., Lorenzen S., Eriksson M., Gambarotti M., Tunn P.U., Jebsen N.L., Cesari M., von Kalle T., Ferraresi V., Schwarz R., Bertulli R., Kasparek A.K., Grignani G., Krasniqi F., Sorg B., Hecker-Nolting S., Picci P., Reichardt P. EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. Tumori. 2018;104(1):30-36.
  6. Markiewicz K., Zeman K., Kozar A., Gołebiowska-Wawr-zyniak M. Evaluation of selected cytokines in children and adolescents with osteosarcoma at diagnosis - preliminary report. Med. Wieku Rozwoj. 2011;15(1):25-31.
  7. Gelderblom H., Jinks R.C., Sydes M., Bramwell V.H., van Glabbeke M., Grimer R.J., Hogendoorn P.C., McTiernan A., Lewis I.J., Nooij M.A., Taminiau A.H., Whelan J.; European Osteosarcoma Intergroup. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur. J. Cancer. 2011;47(6):895-902.
  8. Whelan J.S., Jinks R.C., McTiernan A., Sydes M.R., Hook J.M., Trani L., Uscinska B., Bramwell V., Lewis I.J., Nooij M.A., van Glabbeke M., Grimer R.J., Hogendoorn P.C., Taminiau A.H., Gelderblom H. Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Ann. Oncol. 2012;23(6):1607-1616.
  9. McTiernan A., Jinks R.C., Sydes M.R., Uscinska B., Hook J.M., van Glabbeke M., Bramwell V., Lewis I.J., Taminiau A.H., Nooij M.A., Hogendoorn P.C., Gelderblom H., Whelan J.S. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup. Eur. J. Cancer. 2012;48(5):703-712.
  10. Gershtejn E.S., Kushlinskij D.N., Adamjan L.V., Teresh-kina I.V., Laktionov K.P. Matriksnye metalloprotei-nazy i ih tkanevye ingibitory v klinicheskom techenii i prognoze raka jaichnikov. Molekuljarnaja meditsina. 2013;6:11-20 (Gershteyn Ye.S., Kushlinskiy D.N., Adamyan L.V., Tereshkina I.V., Laktionov K.P. Matriksnyye metalloproteinazy i ikh tkanevyye ingibitory v klinicheskom techenii i prognoze raka yaichnikov. Mol. Med. 2013;6:11-20).
  11. Kushlinskij N.E., Solov'ev Ju.N., Babkina I.V., Gersh-tejn E.S., Bulycheva I.V. Matriksnye metalloprotei-nazy 2, 7, 9 i tkanevoj ingibitor matriksnyh metallopro-teinaz 1-go tipa v syvorotke krovi bol'nyh opuholjami kostej. Bjulleten' eksperimental'noj biologicheskoj meditsiny. 2010;149(2):194-196 (Kushlinskii N.Ye., Solov'yev Yu.N., Babkina I.V., Gershteyn Ye.S., Bulycheva I.V. Matriksnyye metalloproteinazy 2, 7, 9 i tkanevoy ingibitor matriksnykh metalloproteinaz 1-go tipa v syvorotke krovi bol'nykh opukholyami kostey. Byull. Eksp. Biol. Med. 2010;149(2):194-196).
  12. Babkina I.V., Bondarev A.V., Schupak M.Ju., Bulycheva I.V., Solov'ev Ju.N., Mahson A.N. Otdalennye rezul'taty le-chenija bol'nyh sarkomami kostej s uchetom soderzhanija metalloproteinaz v syvorotke krovi. Al'manah kli-nicheskoj meditsiny. 2015;41:40-45 (Babkina I.V., Bondarev A.V., Shchupak M.Yu., Bulycheva I.V., Solov'yev Yu.N., Makhson A.N. Otdalennyye rezul'taty lecheniya bol'nykh sarkomami kostey s uchetom soderzhaniya metalloproteinaz v syvorotke krovi. Al'manakh klinicheskoy meditsiny. 2015;41:40-45)